A drug called Geffy 250 MG Gefitinib Tablet is used to treat non-small cell lung cancer (NSCLC), which is brought on by particular genetic mutations in the EGFR gene. The active component of Geffy tablets, gefitinib, is a member of the medication class known as tyrosine kinase inhibitors (TKIs). It functions by preventing EGFR from functioning, which aids in reducing the growth and spread of cancer cells in the lungs. Orally administered Geffy 250 MG Gefitinib Tablets are typically indicated for EGFR-mutant patients with advanced or metastatic non-small cell lung cancer. Skin rash, diarrhoea, and changes in liver function are examples of typical adverse effects. To reduce potential adverse effects and guarantee therapy effectiveness in patients with NSCLC, regular medical monitoring is crucial throughout the course of the treatment.
250 Geffy MG The primary indication for Gefitinib Tablet is the treatment of non-small cell lung cancer (NSCLC), which is brought on by particular genetic mutations in the EGFR gene. Indications include the following:
1. NSCLC Patients with Advanced or Metastatic NSCLC Who Have EGFR Mutations: Geffy is given for patients with EGFR mutation-positive NSCLC.
2. First-Line therapeutic: It is a first-line therapeutic option for people with NSCLC that has an EGFR mutation.
250 Geffy MG The degree of the side effects that can be caused by taking a gefitinib tablet varies from person to person. Typical negative consequences could be:
1. Skin Rash: Gefitinib may cause a skin rash, which can be treated under a doctor's supervision.
2. Some patients may have diarrhoea while receiving therapy.
3. Gefitinib has the potential to make a person feel queasy and throw up.
4. Patients may feel weary or weak due to fatigue.
5. Gefitinib can alter liver function tests, which can result in abnormalities.
6. Rarely, the drug gefitinib may cause interstitial lung disease (ILD), a lung disorder that can make breathing difficult.
7. Nail Changes: Some people may notice changes in the way their nails look.
8. Gefitinib has been linked to anorexia through decreasing appetite.
9. Patients may get oral sores or ulcers.
10. Gefitinib may result in dry eyes or eye discomfort.
11. Gefitinib may have an impact on abnormal kidney function.
Medical practitioners must regularly follow patients while they are receiving treatment with Geffy 250 MG Gefitinib Tablet. Any symptoms that warrant further investigation should be reported right away to the healthcare professional as the medication carries a potential for serious adverse effects. Healthcare professionals with experience treating EGFR-mutated NSCLC, such as oncologists, should be consulted before choosing a course of treatment. During the course of the Geffy treatment, it is imperative to regularly assess liver function and other variables.